Introducing DosoLogic.
A Digital Dosing Co-Pilot
Offering Patient-Centric
Recommendations On-Demand
Interpretable Dosing Insights
Empowering clinical decision support with best-practice pharmacology modelling via a user-friendly interface. This offers actionable guidance for therapy areas including oncology, anti-infectives and immunology.
Seamless Accessiblity
User-led development and integration with prominent electronic health record systems ensures minimal impact to clinical workflows, secure data use and widespread availability at the point-of-care.
Maximised Therapeutic Potential
Dose individualization reduces treatment risk by increasing the likelihood of achieving target therapeutic levels, maximising effect and minimising adverse events. This reduces time in hospital and improves quality of life.
How it Works
01.
Data: patient, sample, regimen info, drug & marker levels collected via EHR integration
02.
Modelling: data used to generate drug-specific pharmacology model for patient population
04.
Recommendation:
multiple dosing options offered alongside predicted outcome
05.
Optimisation: real-world data, continuously improves model predictive performance
Our Health is Personal.
Why Isn't Our Treatment?
One Size Fits All Dosing
Lack of patient-specific insight drives body weight/surface area guided dose selection. This approach does not fully consider the large differences between how patients process their medication.
Variability in Drug Exposure
Adoption of imprecise dosing labels can cause unpredictable or suboptimal drug-levels between patient groups, limiting benefit or increasing toxicity / mortality.
Quality of Life Impact
The impact is inequitable outcomes for underpresented populations, with 1-in-4 cancer survivors suffering from disease related side effects, costing care providers >$500bn per year.
Backed by
Hear from future adopters
Pamela Kearns
Professor of Clinical Paediatric Oncology,
University of Birmingham
“DosoLogic will allow us to individualise the dose of chemotherapy
to maximise effect on the tumour while
minimising the short and long term side effects.”
